Veterinary Pain Management Market Overview
The Veterinary Pain management market was valued at USD 1,352.19 million in 2021 and it is expected to reach USD 1,996.94 million by 2027 at a CAGR of 6.61% during the forecast period, 2022-2027. Some of the factors driving the Veterinary Pain Management market growth include the high prevalence of inflammatory and painful diseases in the animal population. According to an article published by Veterinary Practice News in June 2020, the prevalence of osteoarthritis in dogs was found to be 20%, globally. Similarly, according to an article published by American Animal Health Association in April 2021, approximately 6 million dogs are diagnosed with cancer each year. The Veterinary Cancer Society estimates that 1 in 4 dogs will develop cancer at some point, and nearly 50% of dogs older than 10 will develop some form of cancer.
Download a free sample here – Veterinary Pain Management Market
Key Highlights of the Veterinary Pain Management Market
The veterinary pain management market is fragmented competitive with the presence of both international and local companies. Some of the market players include Ceva Santé Animale, Elanco Animal Health Incorporated, Zoetis Inc., Vetoquinol SA, and Boehringer Ingelheim International Gmbh.
In 2020, the United States Food & Drug Administration approved Cronus Pharma Specialties’ Carprofen Chewable Tablets (generic version of Rimadyl—Zoetis) for dogs. This nonsteroidal anti-inflammatory drug (NSAID) has been proven safe and effective in relieving pain and inflammation associated with osteoarthritis. Furthermore, it helps control postoperative pain associated with soft tissue and orthopedic surgeries.
Check our other latest research on –
Recent Developments in the Veterinary Pain Management Market
In January 2022, the United States Food and Drug Administration (FDA) approved Zorbium (buprenorphine transdermal solution) from Elanco Animal Health as it expands its pain management offerings while addressing an unmet need for veterinary practices.
In January 2022, the United States Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats.
Related Research and Links
List of Key Players in the Veterinary Pain Management Market
Assisi Animal Health
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Chanelle Veterinary Limited
Dechra Pharmaceuticals PLC
Elanco Animal Health Incorporated
Merck and Co Inc.
*List Not Exhaustive
Mordor Intelligence has segmented the global veterinary pain management market based on product, application, animal type, end-user, and geography:
Product (Market Size & Forecast based on Revenue (USD million), 2019-2027)
Application (Market Size & Forecast based on Revenue (USD million), 2019-2027)
Osteoarthritis and Joint Pain
Animal Type (Market Size & Forecast based on Revenue (USD million), 2019-2027)
End-user (Market Size & Forecast based on Revenue (USD million), 2019-2027)
Hospitals and Clinics
Retail Outlets and Others
Geography (Market Size & Forecast based on Revenue (USD million), 2019-2027)
Rest of Asia Pacific
Rest of Europe
Rest of South America
Middle East and Africa
Rest of Middle East and Africa
About Mordor Intelligence
Mordor Intelligence is a market intelligence and advisory firm. Our mission is to map complex business ecosystems across the globe to better predict butterfly effects. To date, we have partnered with 4000+ enterprises across 20 industries, to deliver precise data and actionable insights in over 6000 projects. Our domain-specific teams of research experts continuously track markets, enabling our clients to gain a competitive edge through high-quality market intelligence.
We offer fully tailored intelligence solutions to meet the unique business requirements of any organization. Our deep industry expertise coupled with cross-functional analyst teams ensures we can support the intelligence requirements of even the most specific of business problems.
Company Name: Mordor Intelligence Private Limited
Contact Person: Sai Teja
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
State: Telangana 500008